Ocular Therapeutix™ Reports Third Quarter 2018 Financial Results and Business Update
BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the third quarter ended September 30, 2018 and provided a business update. “It has been another busy quarter highlighted by continued progress on DEXTENZA® as well as the rest of our deep product pipeline,” said Antony Mattessich,